UMC Utrecht molecular diagnostics spinout Genome Diagnostics has won funding from Ampersand Capital Partners and will work with the private equity firm to spur business growth through activities including M&A.
Genome Diagnostics (GenDx), a Netherlands-based molecular diagnostics technology supplier spun out of University Medical Center (UMC) Utrecht, has received an undisclosed sum of funding from private equity firm Ampersand Capital Partners.
Wietse Mulder, one of the spinout’s co-founders and its chief executive, remains majority shareholder following the deal.
Founded in 2005, GenDx markets a suite of tools and services that enable research clients to carry out molecular-level diagnostics for the purposes of evaluating prospective clinical transplants and for testing a patient’s suitability for a given therapeutic drug.
GenDx’s offering includes sequencing tools for DNA analysis and amplification as well as a training school intended to improve the proficiency of lab researchers in using tissue typing equipment.
Ampersand Capital and GenDx will collaborate to stimulate the latter’s business growth both organically and through M&A operations targeting molecular diagnostic products and services.
David Parker and Mike Evans, general partner and operating partner at Ampersand respectively, have joined GenDx’s board of directors.
Wietse Mulder co-founded GenDx with Erik Rozemuller, a former scientist at UMC Utrecht who now acts as the spinout’s senior scientist for bioinformatics. The pair were assisted by Utrecht Holdings, the investment management arm of both UMC Utrecht and University of Utrecht.
